Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2020

01-12-2020 | Diabetic Retinopathy | Research article

VEGF, apelin and HO-1 in diabetic patients with retinopathy: a correlation analysis

Authors: Rensiqin Wu, Zhifeng Zhu, Dandan Zhou

Published in: BMC Ophthalmology | Issue 1/2020

Login to get access

Abstract

Background

It’s necessary to analyze the role of VEGF, apelin, and HO-1 in patients with type 2 diabetes (T2DM), and to evaluate its relevance to diabetic retinopathy (DR).

Methods

T2DM patients who were treated in our hospital from December 1, 2018 to November 30, 2019 were included. T2DM patients were divided into non-DR (NDR) group, non-proliferative DR (NPDR) group, and proliferative DR (PDR) group. and healthy participants were selected as the control group. The value of VEGF, apelin, and HO1 in predicting PDR were analyzed by receiver operating characteristic (ROC) curve, and the relations of VEGF, apelin, HO-1 and clinical factors in PDR patients were analyzed by Pearson correlation analysis.

Results

A total of 295 participants were included. The level of FPG and HbAlc in PDR group were significantly higher than that of other groups (all p < 0.05); the level of VEGF and apelin in PDR group were significantly higher than that of other groups (all p < 0.05), but the level of HO-1 in PDR group were significantly less than that of other groups(p = 0.017); the AUC of VEGF, apelin, HO-1 and combined use was 0.806(95%CI: 0.779–0.861), 0.819(95%CI: 0.765–0.878), 0.808(95%CI: 0.733–0.869) and 0.902(95%CI: 0.822–0.958) respectively, the AUC, sensitivity, specificity of the three combined use was significantly higher than that of single VEGF, apelin, HO-1 use(all p < 0.05). The cutoff values of serum VEGF, apelin, and HO-1 levels for predicting PDR were 163.85 pg/ml, 8.27 ng/ml, and 26.06 mmol/L respectively. Serum VEGF, apelin, and HO-1 in patients with PDR was related to the time course of DM, FPG and HbAlc (all p < 0.05).

Conclusions

VEGF, apelin and HO-1 are related to the progress of DR, and the combined use of VEGF, apelin and HO-1 is beneficial to the diagnosis and treatment of PDR.
Literature
1.
2.
Rami-Merhar B, Frohlich-Reiterer E, Hofer SE. Diabetes mellitus in childhood and adolescence (update 2019). Wien Klin Wochenschr. 2019;131(Suppl 1):85–90.PubMed
3.
Martinez LC, Sherling D, Holley A. The screening and prevention of diabetes mellitus. Prim Care. 2019;46(1):41–52.PubMed
4.
Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21.PubMed
5.
Pivari F, Mingione A, Brasacchio C, Soldati L. Curcumin and type 2 diabetes mellitus: prevention and treatment. Nutrients. 2019;11(8):8–16.
6.
Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I. Advances in the treatment of diabetic retinopathy. J Diabetes Complicat. 2019;33(12):107417.PubMed
7.
Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab. 2019;45(6):517–27.PubMed
8.
Honasoge A, Nudleman E, Smith M, Rajagopal R. Emerging insights and interventions for diabetic retinopathy. Curr Diab Rep. 2019;19(10):100.PubMed
9.
Sivaprasad S, Pearce E. The unmet need for better risk stratification of non-proliferative diabetic retinopathy. Diabet Med. 2019;36(4):424–33.PubMed
10.
Aouiss A, Anka Idrissi D, Kabine M, Zaid Y. Update of inflammatory proliferative retinopathy: ischemia, hypoxia and angiogenesis. Curr Res Transl Med. 2019;67(2):62–71.PubMed
11.
Yang QH, Zhang Y, Zhang XM, Li XR. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and meta-analysis. Int J Ophthalmol. 2019;12(2):302–11.PubMedPubMedCentral
12.
Rodriguez ML, Perez S, Mena-Molla S, Desco MC, Ortega AL. Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies. Oxidative Med Cell Longev. 2019;2019:4940825.
13.
Berrocal MH, Acaba LA, Chenworth ML. Surgical innovations in the treatment of diabetic macular edema and diabetic retinopathy. Curr Diab Rep. 2019;19(10):106.PubMed
14.
Zhou Z, Ju H, Sun M, Chen H. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: a systematic review and meta-analysis. Dis Markers. 2019;2019:9401628.PubMedPubMedCentral
15.
Dayem S, Battah AA, Bohy A, Yousef RN, Ahmed AM, Talaat AA. Apelin, nitric oxide and vascular affection in adolescent type 1 diabetic patients. Open Access Maced J Med Sci. 2017;5(7):934–9.PubMedPubMedCentral
16.
Soualmia H, Midani F, Hadj-Fradj S, Saadi N, Lassoued M, Messoud T, Gharbi M, Ben-Amor Z. The A445C variant in Apelin receptor and diabetic retinopathy in Tunisian patients. Clin Lab. 2017;63(2):379–83.PubMed
17.
Abu El-Asrar AM, Mohammad G, Allegaert E, Ahmad A, Siddiquei MM, Alam K, Gikandi PW, De Hertogh G, Opdenakker G. Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy. Mol Vis. 2018;24:394–406.PubMedPubMedCentral
18.
Gajos-Draus A, Duda M, Beresewicz A. Cardiac and renal upregulation of Nox2 and NF-kappaB and repression of Nox4 and Nrf2 in season- and diabetes-mediated models of vascular oxidative stress in guinea-pig and rat. Physiol Rep. 2017;5(20):14–9.
19.
Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev. 2010;6(5):304–12.PubMed
20.
Malik TG, Ahmed SS, Gul R, Khalil M, Malik AA, Khan M. Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema. Turk J Med Sci. 2018;48(4):833–9.PubMed
21.
Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol. 2001;17(11):983–9.PubMed
22.
Robertson GL. Diabetes insipidus: differential diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(2):205–18.PubMed
23.
Radda S, Bolz M, Egger S, Gasser-Steiner V, Kralinger M, Mennel S, Scholda C, Stolba U, Wedrich A. Die Netzhautkommission der osterreichischen ophthalmologischen G: [diagnosis, treatment and monitoring of diabetic eye disease (update 2019)]. Wien Klin Wochenschr. 2019;131(Suppl 1):164–8.PubMed
24.
Lim RR, Wieser ME, Ganga RR, Barathi VA, Lakshminarayanan R, Mohan RR, Hainsworth DP, Chaurasia SS. NOD-like receptors in the eye: uncovering its role in diabetic retinopathy. Int J Mol Sci. 2020;21(3):1–7.
25.
Shosha E, Fouda AY, Narayanan SP, Caldwell RW, Caldwell RB. Is the arginase pathway a novel therapeutic avenue for diabetic retinopathy? J Clin Med. 2020;9(2):33–40.
26.
Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012.PubMed
27.
Wang W, ACY L. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):2–8.
28.
Terasaki H, Ogura Y, Kitano S, Sakamoto T, Murata T, Hirakata A, Ishibashi T. Management of diabetic macular edema in Japan: a review and expert opinion. Jpn J Ophthalmol. 2018;62(1):1–23.PubMed
29.
Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M, Carrascosa A. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40(9):1107–9.PubMed
30.
Baharivand N, Zarghami N, Panahi F, Dokht Ghafari MY, Mahdavi Fard A, Mohajeri A. Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol. 2012;6:185–91.PubMedPubMedCentral
31.
Chen H, Liu C, Cheng C, Zheng L, Huang K. Effects of Apelin peptides on diabetic complications. Curr Protein Pept Sci. 2018;19(2):179–89.PubMed
32.
Li Y, Bai YJ, Jiang YR, Yu WZ, Shi X, Chen L, Feng J, Sun GB. Apelin-13 is an early promoter of cytoskeleton and tight junction in diabetic macular edema via PI-3K/Akt and MAPK/Erk signaling pathways. Biomed Res Int. 2018;2018:3242574.PubMedPubMedCentral
33.
Yasir M, Senthilkumar GP, Jayashree K, Ramesh Babu K, Vadivelan M, Palanivel C. Association of serum omentin-1, apelin and chemerin concentrations with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus patients. Arch Physiol Biochem. 2019:1–8.
34.
Lu Q, Ma Y, Xu YS, Jiang YR. Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy. Mol Vis. 2014;20:1122–31.PubMedPubMedCentral
35.
Yonem A, Duran C, Unal M, Ipcioglu OM, Ozcan O. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract. 2009;84(3):219–23.PubMed
36.
Du JH, Li X, Li R, Xu L, Ma RR, Liu SF, Zhang Z, Sun HZ. Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients. Int J Ophthalmol. 2014;7(6):968–73.PubMedPubMedCentral
37.
Tao Y, Lu Q, Jiang YR, Qian J, Wang JY, Gao L, Jonas JB. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(8):4237–42.PubMed
38.
Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004;325(2):395–400.PubMed
39.
Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina. 2011;31(1):161–8.PubMed
40.
Castilho A, Aveleira CA, Leal EC, Simoes NF, Fernandes CR, Meirinhos RI, Baptista FI, Ambrosio AF. Heme oxygenase-1 protects retinal endothelial cells against high glucose- and oxidative/nitrosative stress-induced toxicity. PLoS One. 2012;7(8):e42428.PubMedPubMedCentral
41.
He M, Pan H, Xiao C, Pu M. Roles for redox signaling by NADPH oxidase in hyperglycemia-induced heme oxygenase-1 expression in the diabetic retina. Invest Ophthalmol Vis Sci. 2013;54(6):4092–101.PubMed
42.
Grochot-Przeczek A, Dulak J, Jozkowicz A. Heme oxygenase-1 in neovascularisation: a diabetic perspective. Thromb Haemost. 2010;104(3):424–31.PubMed
43.
Fan J, Xu G, Jiang T, Qin Y. Pharmacologic induction of heme oxygenase-1 plays a protective role in diabetic retinopathy in rats. Invest Ophthalmol Vis Sci. 2012;53(10):6541–56.PubMed
44.
Bucolo C, Drago F, Maisto R, Romano GL, D'Agata V, Maugeri G, Giunta S. Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2-mediated activation of the Nrf2/HO-1 pathway. J Cell Physiol. 2019;234(10):17295–304.PubMed
45.
Shibagaki F, Ishimaru Y, Sumino A, Yamamuro A, Yoshioka Y, Maeda S. Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-induced loss of retinal neuronal cells in mice. Neurochem Res. 2020.
46.
McAnally D, Siddiquee K, Gomaa A, Szabo A, Vasile S, Maloney PR, Divlianska DB, Peddibhotla S, Morfa CJ, Hershberger P, et al. Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS One. 2018;13(9):e0202436.PubMedPubMedCentral
Metadata
Title
VEGF, apelin and HO-1 in diabetic patients with retinopathy: a correlation analysis
Authors
Rensiqin Wu
Zhifeng Zhu
Dandan Zhou
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-020-01593-9

Other articles of this Issue 1/2020

BMC Ophthalmology 1/2020 Go to the issue

Research article

A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Research article

Dual effect of the Valsalva maneuver on autonomic nervous system activity, intraocular pressure, Schlemm’s canal, and iridocorneal angle morphology

Research article

Assessment of optometrists’ knowledge, skills and practice on cataract: a cross-sectional study from Kisumu County, Western Kenya

Case report

A case report of fulminant endophthalmitis caused by Streptococcus dysgalactiae in a patient with traumatic corneal laceration

Case report

Concurrent tuberculous chorioretinitis with choroidal neovascularization and tuberculous meningitis: a case report

Research article

Effect of silicone oil on peripapillary capillary density in patients with rhegmatogenous retinal detachment